Leanova

Ethinylestradiol and Levonorgestrel, the active ingredients in Leanova, are a combined oral contraceptive presented as oral tablets for oral use. The formulation follows European Union standards and is intended for women seeking reliable, reversible contraception. They prevent pregnancy by inhibiting ovulation and altering cervical mucus and the endometrial lining in women of reproductive age.

GNH USA supplies Leanova as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets, and timely delivery.

Leanova, a combined oral contraceptive, works on the hormonal regulation of the menstrual cycle to prevent pregnancy.

Contraception: prevents ovulation and thereby avoids pregnancy. Family planning: provides reliable hormonal control for women seeking to delay or space pregnancies. Menstrual regulation: can reduce heavy menstrual bleeding and dysmenorrhea while maintaining contraceptive efficacy. Hormone therapy adjunct: may be used under medical supervision to manage certain estrogen‑deficient conditions. Pregnancy prevention: offers a reversible method for women desiring long‑term birth control. Cycle control: helps establish a predictable menstrual cycle pattern for users.

Leanova may be associated with a range of adverse reactions, from mild and transient to serious and potentially life‑threatening.

Common Side Effects: - Nausea: mild stomach upset, especially during the first cycles. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: mild to moderate headache episodes. - Irregular bleeding or spotting: occasional breakthrough bleeding between periods.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis, pulmonary embolism, stroke, or myocardial infarction, particularly in women with risk factors. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis requiring immediate medical attention. - Liver dysfunction: jaundice, hepatic adenoma, or abnormal liver function tests.

When prescribing Leanova, clinicians should consider several precautionary measures to ensure patient safety.

Pregnancy contraindication: product is classified as Category X and must not be used during pregnancy. Smoking risk: avoid in women over 35 who smoke due to increased thrombotic risk. Cardiovascular history: assess for prior thromboembolic events, hypertension, or coronary artery disease before initiation. Liver disease: use with caution in patients with hepatic impairment or active liver disease. Drug interactions: review concomitant medications that may affect hormonal efficacy or increase adverse effects. Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Leanova can interact with other medicines, altering its contraceptive effectiveness or increasing the risk of side effects.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce hormone levels and contraceptive efficacy. - Combined estrogen therapies (e.g., hormone replacement therapy): increase risk of thromboembolic complications. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole, itraconazole): can increase plasma concentrations of hormonal components, requiring monitoring for side effects. - Protease inhibitors (e.g., ritonavir): may affect hormone metabolism and alter contraceptive reliability. - Herbal supplements such as St. John’s wort: may decrease hormone levels and reduce contraceptive protection.